PD-L1 mAb administration served as a blocker of the checkpoint inhibitor, preventing the cancer cells from silencing the immune activity of CD8+ cytotoxic T cells via their PD-L1 to PD-1 binding. This evidence concerns the gene CD8A and cancer.